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Copy number variations (CNVs) have been implicated in human
diseases. However, it remains unclear how they affect immune
dysfunction and autoimmune diseases, including rheumatoid arthritis
(RA). Here, we identified a novel leukocyte-specific protein 1 (LSP1)
deletion variant for RA susceptibility located in 11p15.5. We replicated
that the copy number of LSP1 gene is significantly lower in patients
with RA, which correlates positively with LSP1 protein expression
levels. Differentially expressed genes in Lsp1-deficient primary T cells
represent cell motility and immune and cytokine responses. Func-
tional assays demonstrated that LSP1, induced by T-cell receptor
activation, negatively regulates T-cell migration by reducing ERK
activation in vitro. In mice with T-cell–dependent chronic inflam-
mation, loss of Lsp1 promotes migration of T cells into the target
tissues as well as draining lymph nodes, exacerbating disease se-
verity. Moreover, patients with RA show diminished expression of
LSP1 in peripheral T cells with increased migratory capacity, sug-
gesting that the defect in LSP1 signaling lowers the threshold for
T-cell activation. To our knowledge, our work is the first to dem-
onstrate how CNVs result in immune dysfunction and a disease
phenotype. Particularly, our data highlight the importance of
LSP1 CNVs and LSP1 insufficiency in the pathogenesis of RA and
provide previously unidentified insights into the mechanisms un-
derlying T-cell migration toward the inflamed synovium in RA.
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Cell migration plays a central role in maintaining homeostasisand coping with a wide spectrum of perturbing stimuli for
multicellular organisms. Wound healing involves the migration
of several cell types, and the migration of leukocytes into lymph
nodes and inflamed tissue is required for the development of
immune responses (1). Moreover, excessive and uncontrolled
infiltration of distinct effector leukocytes into particular organs
or tissue components is a characteristic pathology found in var-
ious chronic inflammatory diseases including psoriasis, Crohn’s
disease, ulcerative colitis, multiple sclerosis, asthma, atherosclerosis,
and rheumatoid arthritis (RA) (1, 2).
RA is an autoimmune disorder that engages an uncontrolled
influx of inflammatory cells to the joints, leading to persistent
synovitis and tissue destruction (3). T cells, as one of the most
abundant cell population in the RA synovium, are aberrantly
activated in RA to drive chronic inflammation and joint de-
struction (4). RA T cells interact with other immune and resident
cells, including B cells, macrophages, synoviocytes, and osteoclasts
by secreting a variety of cytokines and chemokines and/or by direct
cell-to-cell contact, and ultimately boost their proinflammatory
action (5). The role that diverse T-cell populations play in the
induction, amplification, and maintenance of inflammatory ar-
thritis has been elucidated in various animal models of RA (6).
Abnormal activation of RA T cells is associated with abnormal
T-cell receptor (TCR) activation and the Ca2+ signaling pathway
(7, 8). Successful outcomes for patients with RA treated with
T-cell regulators, including abatacept (CTLA4-Ig) (9), highlight
the importance of activated T cells in the progression of RA.
The pathologic phenotype of cellular components of a certain
disease depends on the quantitative and/or qualitative abnor-
malities of disease-associated proteins, which might be caused by
a perturbation of fundamental regulatory mechanisms, including
transcription, RNA processing, and mRNA degradation and
translation, in addition to genetic alterations (10). An important
causal link between genomic variation and phenotypic differ-
ence includes SNPs and DNA copy number variations (CNVs).
Through genome-wide association studies (GWASs), a number
of non-MHC genes that potentially contribute to RA suscepti-
bility have been identified (11). However, the majority of SNPs
have modest effects and do not represent the full spectrum of
genetic variations. Recently, it has been suggested that CNVs
are an important source of human genetic variation—in some
analyses potentially as important as SNPs (12). CNV of indi-
vidual genes can result in cellular and organismal abnormalities,
and cumulative effects of CNVs underlie many human diseases,
including autoimmune diseases (12). A few candidate CNVs for
RA susceptibility, such as CCL3L1 and FCGR3B, have been
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suggested (13, 14), but they have not been successfully replicated
or functionally validated, suggesting that other CNVs may be yet
found that significantly contribute to the overall risk model.
T-cell infiltration into the synovial compartment is an essential
step for the progression of RA. T-cell accumulation primarily
reflects migration rather than local proliferation (3). Therefore,
regulatory mechanism of T-cell trafficking into the synovium
has been focused mainly on endothelial activation in synovial
microvessels, which increases the expression of adhesion mole-
cules and chemokines. However, the intrinsic migratory mecha-
nism of T cells and its alteration in patients with RA has
garnered less attention (15). Given the importance of genetic
elements in determining pathologic phenotype (16), it is neces-
sary to explore the impact of genetic variations, such as CNV, on
immune dysfunction (e.g., T-cell activation) to better understand
the susceptibility and pathogenesis of RA. For this goal, we
screened RA-associated CNVs across the whole genome in 500
subjects and validated them in 1,565 Korean subjects and 423
white subjects.
Results
Loss of LSP1 Gene Is Significantly Associated with RA Susceptibility.
We performed a GWAS to identify RA-associated CNVs in the
Korean population. Ultimately, a total of 31,373 CNVs were
identified from 500 samples (100 patients with RA and 400
healthy individuals; SI Appendix, Table S1). The mean and me-
dian numbers of CNVs identified per individual genome were
62.7 and 45, respectively (range, 16-1,021), and the median size
of CNVs was 18.6 kb (range, 248 bp to 8.6 Mb). Based on the
CNVs, we defined 3,936 CNV regions (CNVRs) as described
elsewhere (17). Using the 3,936 CNVRs, we performed logistic
regression analysis after adjusting for the effects of age and sex,
and seven CNVRs were found to be significantly associated
with the risk of RA (false discovery rate < 0.01; SI Appendix,
Table S2). There are three protein-coding genes (LSP1,
TNNT3, and UGT2B28) in the seven significant CNVRs.
Among them, leukocyte-specific protein 1 (LSP1) gene, located
in the deletion CNVR in 11p15.5, is a specific leukocyte marker
(18) with a demonstrated role in acute inflammation (19, 20).
Therefore, we selected the deletion CNVR in 11p15.5, where
the LSP1 gene is located, as a novel target gene for RA suscepti-
bility, and performed independent replication and functional
analyses. To this end, target-specific genomic quantitative PCR
(qPCR) for the LSP1 gene was performed in a larger Korean co-
hort group (n = 1,565) for independent replication: 599 patients
with RA and 966 healthy control individuals (SI Appendix, Table
S1). We also performed the same replication in a white cohort
group (n = 423, 165 patients with RA and 258 healthy individuals).
Details of the study subjects, defining CNVRs, and qPCR for ge-
nomic DNA are described in Materials and Methods and in SI
Appendix, Materials and Methods. As expected, the proportion of
individuals with fewer than two copies of the LSP1 gene was sig-
nificantly higher in patients with RA (10.5%, 63 of 599) than in
controls [0.7%, 7 of 966; odds ratio (OR) = 16.1, 95% CI = 7.3–
35.4; P = 3.68 × 10−20) in the Korean cohort (Fig. 1A). The pro-
portion of the LSP1 deletion variants in the white cohort was
consistent with the profile in the Korean cohort: 8.5% (14 of 165)
in patients with RA vs. 1.6% (4 of 258) in controls (OR = 5.9, 95%
CI = 1.9–18.2; P = 8.59 × 10−4). When we merged the two repli-
cation sets together, the significance became higher: 10.1% (77 of
764) in patients with RA vs. 0.9% (11 of 1,224) in controls (OR =
12.4, 95% CI = 6.5–23.4; P = 2.25 × 10−22). After adjusting for the
effects of age and sex by logistic regression, the individuals with
fewer than two copies had a significantly higher risk of RA than
the individuals with two or more copies (OR = 18.9, 95% CI = 8.4–
42.5, P = 1.10 × 10−12).
We also compared the LSP1 protein expression level in pe-
ripheral blood mononuclear cells (PBMCs) between patients
with RA and controls. For this analysis, 22 patients with RA and
24 healthy controls, whose PBMCs were available for Western
blotting, were examined. As in the LSP1 CNVR association, the
LSP1 protein level was significantly lower in the RA group than
in the control group (0.52 ± 0.19 vs. 0.65 ± 0.14; P = 0.01; Fig.
1B). Moreover, a positive correlation between LSP1 protein
expression level and the copy number status of LSP1 was ob-
served in patients with RA and controls (R2 = 0.450, P = 0.004 in
RA; R2 = 0.519, P = 6.0 × 10−6 in controls; and R2 = 0.533, P =
3.9 × 10−8 in total by Spearman rank test; Fig. 1C).
Fig. 1. LSP1 copy number and LSP1 expression profiles in patients with RA. (A) Frequency distribution of LSP1 genomic copy number. (Left) Distribution
patterns of LSP1 copy numbers in patients with RA (solid bar; n = 599) and normal controls (open bar; n = 966) from Korea. (Middle) Distribution patterns of
LSP1 copy numbers in white patients with RA (solid bar; n = 165) and normal controls (open bar; n = 258) from the United States. (Right) Overall distribution
patterns of LSP1 copy numbers from Korea and the United States (*P < 0.05 and **P < 0.001). (B) LSP1 expression in PBMCs of patients with RA and healthy
controls. A ratio of LSP1 protein expression relative to GAPDH protein (LSP1/GAPDH) was measured by Western blot analysis. (C) Correlation between LSP1
protein expression level and the copy number status of LSP1 gene in PBMCs of RA and control groups.
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LSP1 Is Increased in Primary Human T Cells by TCR Triggering. LSP1 is
an intracellular Ca2+ and F-actin binding protein (21) that reg-
ulates murine neutrophil migration and chemotaxis (22). How-
ever, its expression and function in autoreactive T cells, including
RA T cells, remain unaddressed. Based on our finding that LSP1
copy number negatively correlated with RA risk but positively
correlated with LSP1 expression, we postulated that LSP1 is a
negative regulator of RA development and sought to ascertain
the clinical and functional relevance of altered LSP1 expression
to development and progression of RA. As a preliminary ex-
periment, we assayed the expression of LSP1 in normal PBMCs
and Jurkat T cells by flow cytometry. As seen in SI Appendix, Fig.
S1A, LSP1 was expressed in CD4+ T cells, CD8+ T cells, and
monocytes. LSP1 also was expressed in Jurkat T cells. Western
blot analysis revealed LSP1 protein with a molecular mass of
52 kDa at high levels in primary human T cells, confirming the
presence of full-length LSP1 (SI Appendix, Fig. S1A, Inset).
Activated T cells play central roles in the initiation and per-
petuation of RA (3, 4). We next determined which types of T-cell
activators induce LSP1 expression. It is well known that TCR
signaling is triggered by phytohemagglutinin (PHA) or anti-CD3/
CD28 Ab (23). We investigated if these stimuli affect LSP1 ex-
pression in T cells. As shown in SI Appendix, Fig. S1B, stimula-
tion of T cells with anti-CD3/CD28 Ab or PHA increased LSP1
expression in CD4+ and CD8+ T cells of healthy subjects, in-
dicating that LSP1 can be induced by TCR stimulation. Addi-
tionally, phorbol myristate acetate (PMA) plus ionomycin, a Ca2+
activator, up-regulated LSP1 expression in normal human T cells
as well as Jurkat T cells (SI Appendix, Fig. S1 B, D, and E), sug-
gesting that Ca2+ signaling is required for LSP1 up-regulation in
primary T cells, which is in accord with previous reports (24, 25).
Another Ca2+ activator, TNF-α, also time-dependently increased
LSP1 expression in Jurkat cells (SI Appendix, Fig. S1E).
To test if TCR triggering by a specific antigen increases LSP1
expression in vivo, we determined the LSP1 protein expression
level in a mouse model of collagen-induced arthritis (CIA), a
classic model of experimental arthritis mediated by antigen-
activated T cells (26). As expected, LSP1 expression was higher
in CD4+ and CD8+ T cells in draining lymph node of mice with
CIA than in those of nonarthritic normal mice (SI Appendix, Fig.
S1F). Taken together, LSP1 is expressed in primary T cells and
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Fig. 2. LSP1 inhibition of T-cell migration. (A) Hierarchical clustering of DEGs in the two comparisons: Lsp1(−/−)/Lsp1(+/+) without anti-CD3/28 Abs (first
column) or Lsp1(−/−)/Lsp1(+/+) with anti-CD3/28 Abs (second column). After hierarchical clustering using Euclidean distance as a dissimilarity measure and
complete linkage method, we identified eight clusters (C1-C8) that reflect all possible combinations of up-regulation (red) and down-regulation (green)
patterns of the DEGs in the two comparisons (SI Appendix, Table S3). The numbers in parentheses show the number of DEGs in each cluster. Color bar in-
dicates the gradient of log2 fold change. (B) Heat map shows Gene Ontology biological processes (GOBPs) and Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways represented by up- or down-regulated genes in Lsp1(−/−) T cells, compared with Lsp1(+/+) T cells, in the absence and presence of anti-CD3/28 Abs.
Color bar indicates gradient of Z score N−1(1 − P) where P is P value computed by DAVID and N−1(·) is the inverse standard normal distribution. Migration-related
GOBPs or KEGG pathways are labeled in red. (C) In vitro migration of CD4+ T cells (5 × 105 cells) obtained from the spleens of Lsp1-deficient (n = 5) and WT mice
(n = 5). Migration assays were performed in transwell chambers in the presence or absence of SDF1α (100 ng/mL) or 10% (vol/vol) FBS in triplicate. The
results are the mean ± SD. Expression of CXCR4 (a specific SDF1 receptor) determined by flow cytometry is presented on the right. Gray-colored histogram
indicates isotype control. (D) Suppression of SDF1-induced T-cell migration by LSP1 overexpression. Human recombinant SDF1α (100 ng/mL), MCP-1 (100 ng/mL),
IL-6 (100 ng/mL), or 10% FBS was added to the lower chamber of the transwell inserts. The Jurkat T cells (1 × 106 cells) were loaded to the upper chamber and
allowed to migrate for 4 h. The number of migrated cells were counted manually (Left) or determined by flow cytometry analysis (Right).
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Jurkat T cells, and its expression is up-regulated by TCR ligation
or intracellular Ca2+ activation.
LSP1 Negatively Regulates T-Cell Migration. We next investigated
the function of LSP1 in T-cell biology. For an unbiased and
systematic analysis of LSP1 effect on T cells, we performed
global transcriptome profiling of T cells obtained from Lsp1-
deficient [i.e., Lsp1(−/−)] and WT mice in the presence or absence
of anti-CD3/CD28 Abs. By using an integrative statistical method
reported previously (27), we identified 1,043 and 677 differentially
expressed genes (DEGs) in the two comparisons: Lsp1(−/−) vs.
Lsp1(+/+) T cells without and with anti-CD3/CD28 Abs (Fig. 2A
and SI Appendix, Table S3 and Dataset S1). A substantial pro-
portion of the DEGs (303 genes; 21.4%) were shared in the two
sets of DEGs (SI Appendix, Fig. S2A). To investigate the cellular
processes represented by the DEGs, we performed functional
enrichment analysis for the up- and down-regulated DEGs using
Database for Annotation, Visualization, and Integrated Dis-
covery (DAVID) software (28). As a result, we found that the
up-regulated genes under TCR-activated conditions were pre-
dominantly associated with migration-related processes, including
leukocyte migration, cell migration/motility, and chemotaxis (Fig.
2B and SI Appendix, Table S4). Other processes governed by
LSP1 include cytokine–cytokine receptor interaction, response
to wounds, innate immune response, and Ca2+ ion homeostasis
(SI Appendix, Table S4).
As migration-related processes were predominantly enriched
by the DEGs, the in vitro functional assay for T-cell migration
was performed in transwell chambers. As shown in Fig. 2C,
the migration of CD4+ T cells isolated from the splenocytes of
Lsp1-deficient mice was significantly enhanced irrespective
of the presence of FBS compared with that of WT littermates.
T-cell migration through the bloodstream to the target tissue is
driven by chemokines. For example, stromal cell-derived factor-1
(SDF1)/CXCR4 axis induces Ca2+ flux in T cells (29) and pro-
motes T-cell migration toward the inflamed joints, thereby
contributing to RA pathology (30). In this study, we found that
Lsp1(−/−) T cells exhibited increased migration in response to
SDF1 compared with WT T cells (Fig. 2C). This is not attributable
to the receptor level because CXCR4 expression on T cells was
not different between Lsp1-deficient and WT mice as deter-
mined by flow cytometry (Fig. 2C). Additionally, there was no sig-
nificant difference in the production of cytokines, including IL-10,
TNF-α, IFN-γ, and IL-2 by T cells upon anti-CD3/CD28 stimulation
(SI Appendix, Fig. S3 A and B), indicating that these cytokines do not
contribute to increased T-cell migration as a result of Lsp1 deficiency.
The CNV in patients with RA yields a less dramatic change in
LSP1 expression than complete gene loss and may be more relevant
to RA pathogenesis. Thus, we investigated if Lsp1 haploinsufficiency
in mice also increases T-cell migration. As expected, Lsp1(+/−)
T cells still showed an increased migration in response to media,
10% (vol/vol) FBS, and SDF1 compared with Lsp1(+/+) T cells
(SI Appendix, Fig. S4), but its extent was attenuated compared
with Lsp1(−/−) T cells. For example, compared with WTmice, T-cell
migration in response to media, 10% FBS, and SDF1 was increased
by 1.9, 1.6, and 2.2 fold for Lsp1(+/−) mice, respectively, but was
increased by 4.4, 2.4, 3.6 fold for Lsp1(−/−) mice, respectively
(Fig. 2C and SI Appendix, Fig. S4). These results indicate a gene
dose effect of Lsp1 on T-cell migration, suggesting that even a 50%
reduction of Lsp1 gene is sufficient to affect T-cell function.
Based on the data in murine T cells, we wanted to determine
whether LSP1 overexpression regulates human T-cell migration. To
this end, we transfected the LSP1 cDNA tagged withGFP into Jurkat
T cells by electroporation. After stable transfection of LSP1-GFP
fusion gene, LSP1 protein as well as GFP was highly detected in
Jurkat cells (SI Appendix, Fig. S1C). In contrast to LSP1-deficient
cells, LSP1-overexpressing Jurkat T cells showed a lesser degree of
migration in response to SDF1 in transwell chambers than the
control cells (Fig. 2D). However, T-cell migration stimulated with
10% FBS, MCP-1, or IL-6 was not different between LSP1-
overexpressing cells and control cells. The LSP1-dependent de-
crease in T-cell migration was independent of cell proliferation
because BrdU incorporation revealed no difference between the
two types of cells. Moreover, the number of cells counted manu-
ally was not different between the two cell lines over the 4 d of
culture, indicating that LSP1 is not directly involved in T-cell
proliferation (SI Appendix, Fig. S3C). In parallel, IL-2 production
was not different between the two cell lines stimulated with PHA
or anti-CD3/CD28 Ab (SI Appendix, Fig. S3D).
LSP1 Directly Interacts with pERK to Regulate T-Cell Migration. SDF1
stimulates ERK (29), which promotes T-cell migration (31).
Therefore, we investigated to determine if ERK is a downstream
target of LSP1 for T-cell migration. As shown in Fig. 3A, the
expression level of phosphorylated ERK (pERK) was reduced in
LSP1-overexpressing Jurkat T cells upon TCR and SDF1 stim-
ulation, as determined by Western blot analysis. Flow cytometry
analysis also showed that TCR or SDF1-induced increases in
pERK activity in Jurkat cells were reduced by LSP1 over-
expression (Fig. 3B). In contrast, TCR triggered-pERK expres-
sion was significantly higher in CD4+ T cells of Lsp1(−/−) mice
than in those of Lsp1(+/+) mice (Fig. 3C), indicating that LSP1 is
a negative regulator of ERK activation. Moreover, an immuno-
precipitation assay revealed that LSP1 coimmunoprecipitated
with pERK, (Fig. 3D), demonstrating that LSP1 directly interacts
with pERK, and thereby interferes with TCR-dependent ERK
phosphorylation. Additionally, the SDF1-induced increase in
T-cell migration, noted predominantly in Lsp1-deficient CD4+
T cells, was almost completely abrogated by the ERK inhibitor
PD98059 (Fig. 3E). This effect was not a result of the nonspecific
cytotoxicity of PD98059 as indicated by an 3-(4,5-dimethylthiazolyl)-
2,5-diphenyltetrazolium bromide (MTT) assay (Fig. 3E, Inset).
Overall, these results suggest that LSP1 inhibits T-cell migration by
regulating the extent of ERK phosphorylation.
To investigate LSP1-pERK axis-dependent target genes that are
involved in T-cell migration, we compared 677 Lsp1(−/−)/Lsp1(+/+)
DEGs in the presence of anti-CD3/CD28 Abs with 1359 migration-
related genes (e.g., leukocyte migration, cell migration/motility and
chemotaxis) obtained from the AmiGO database (32). We iden-
tified 67 shared genes (P < 1 × 10−6) and then examined whether
the shared genes are regulated by ERK-downstream transcription
factors (TFs; SI Appendix, Materials and Methods). As a result, nine
ERK-downstream TFs had significant numbers of target genes (P <
0.05) in the 67 shared genes, suggesting that the shared migration-
related genes are regulated by the ERK pathway (SI Appendix, Fig.
S2B). Subsequently, we selected the nine representative genes from
LSP1-controlled and ERK-regulated DEGs (SI Appendix, Tables
S5 and S6), and validated differential expression by using quanti-
tative real-time PCR. As shown in Fig. 3F, IL-1β, Csf1r, Ptgs2, Ccl2,
Ccl19, and Cxcl9 mRNA expressions were increased in anti-CD3–
activated T cells of Lsp1(−/−) mice compared with those of Lsp1(+/+)
mice, but Sox9, IL-4, and Gli3 expressions were decreased in the
same cells. Conversely, LSP1-overexpressing Jurkat T cells showed
lower levels of IL-1β, Csf1r, Ptgs2, Ccl2, Ccl19, and Cxcl9 mRNA
expression, but higher levels of LSP1, Sox9, IL-4, and Gli3 mRNA
expression, than control cells (Fig. 3F). Collectively, these data sup-
port the view that LSP1 controls T-cell migration via its interaction
with pERK.
T-Cell–Dependent Chronic Inflammation Is Enhanced in Lsp1-Deficient
Mice. Delayed-type hypersensitivity (DTH) is a useful approach to
evaluating T-cell–mediated immune responses (33). To investigate
the pathology associated with LSP1 expression in vivo, DTH re-
actions were elicited in Lsp1-deficient and WT mice by injecting
methylated BSA (mBSA) intradermally as a T-cell antigen. The
result showed that footpad swelling was significantly greater in
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Lsp1(−/−) mice than in Lsp1(+/+) mice, as assessed 24 h after
booster immunization (Fig. 4A). Histological analysis revealed that
edema and total leukocyte infiltration were increased in the
inflamed dermis of Lsp1-deficient mice (Fig. 4 B and C). Infiltration
of T cells into the dermis, as determined by immunohistochemistry
using anti-CD3 Ab, was also more pronounced in Lsp1-deficient
mice than in WT mice (Fig. 4 B and C). In parallel, mBSA-specific
serum IgG concentrations were significantly higher in Lsp1-
deficient mice than in WT mice (Fig. 4C).
Seven days after booster immunization, we assayed changes in T-
cell populations in the draining lymph nodes by using flow cytometry.
The frequency of CD4+ T cells, but not CD8+ T cells, was signifi-
cantly higher in the lymph nodes of Lsp1-deficient mice than in those
of WT mice (Fig. 4D), suggesting that antigen-activated T cells of
Lsp1-deficient mice also have greater migratory and homing capacity.
To confirm this observation, we isolated CD4+ T cells from the
spleen and draining lymph nodes of mice with DTH, and then de-
termined their migration in vitro (Fig. 4 E and F). As seen in Fig. 4E,
splenic CD4+ T-cell migration in transwell chambers was increased
by stimulation with 10% FBS and SDF1 in Lsp1-deficient and WT
mice, and the increase was more pronounced in Lsp1-deficient
CD4+ T cells. An experiment conducted with CD4+ T cells
isolated from the lymph nodes of Lsp1-deficient mice showed
similar results, suggesting that migration of antigen-activated
T cells is also controlled by LSP1. Of note, the loss of Lsp1 did
not affect the overall ratio (percentage gated) of naive, central
memory, and effector memory populations of CD4+ and CD8+
T cells (SI Appendix, Fig. S5), eliminating the possibility that in-
creased T-cell migration in Lsp1(−/−) mice might be caused by a
difference in T-cell subsets between Lsp1(−/−) and Lsp1(+/+) mice.
Lsp1 Deficiency Increases T-Cell–Dependent Arthritis.Antigen-induced
arthritis (AIA) is another T-cell–driven disease model (34).
Thus, we investigated the effect of LSP1 on the severity of AIA.
After administration of mBSA into the ankle joint of preimmu-
nized mice, arthritic signs, indicated by joint swelling and redness,
rapidly developed and peaked at day 1 in Lsp1-deficient and WT
mice, but they were more prominent in the former. At day 3, the
foot swelling remained persistent in Lsp1-deficient mice while
regressing in WT mice (Fig. 5A). Concomitantly, Lsp1-deficient
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anti-CD3/CD28 for 20 min. The pERK expression was determined byWestern blot analysis. A ratio of pERK1/2 relative to total Erk1/2 expression is presented on
the right (*P < 0.05). (D) Immunoprecipitation assay to detect LSP1 binding to pERK. LSP1-overexpressing or control Jurkat T cells were stimulated with anti-
CD3/CD28 for 10 min. After cells were incubated with pERK Ab, the LSP1-pERK complexes were precipitated by centrifugation and detected with anti-LSP1
Ab. (E) PD98059 inhibition of SDF1-induced T-cell migration. Splenic T cells were isolated from Lsp1-deficient (−/−) and WT mice and stimulated with SDF1α
(100 ng/mL) in the presence or absence of PD98059 (2 μM), an ERK inhibitor. Cell migration was assessed in transwell chambers. Data are the mean ± SD of five
independent experiments. Cell viability (Insets) was determined by MTT assay. (F) qPCR assays for representative DEGs regulated by ERK-downstream TFs in
Lsp1-deficient [i.e., (−/−)] T cells (Upper) and in Jurkat T cells (Lower), which were stimulated with anti-CD3/28 Abs for 6 h and 12 h, respectively.
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mice had higher antigen-specific IgG levels in their sera than the
WT mice (Fig. 5B). Histological analysis revealed increased soft
tissue edema and inflammatory cell infiltration around the ankle
joints, which were significantly higher in Lsp1-deficient mice.
Moreover, a more dense infiltration of T cells, demonstrated by
anti-CD3 immunostaining, was observed in Lsp1-deficient mice
(Fig. 5 C and D).
Antigen-activated T cells are crucial for the initiation and
perpetuation of chronic inflammatory reactions in RA (3, 4).
However, the expression and function of LSP1 in RA have never
been reported to our awareness. Thus, we examined whether
patients with RA have altered LSP1 protein expression in their
T cells by flow cytometry. As expected, CD4+ T cells of patients
with RA had lower LSP1 expression than those of healthy indi-
viduals (Fig. 6 A and B). CD8+ T cells also showed similar results
(Fig. 6 A and B); these differences were not observed in mono-
cytes (SI Appendix, Fig. S6). Interestingly, the frequency of
LSP1+ cells was significantly higher in matched synovial T cells
than in simultaneously obtained peripheral T cells (Fig. 6B),
which concurs with our data on the increased LSP1 expression in
TCR- or TNF-α–stimulated T cells as well as in arthritic mice (SI
Appendix, Fig. S1). Notwithstanding, RA T cells stimulated with
PHA or anti-CD3/CD28 Abs still showed a lesser induction of
LSP1 expression than T cells of healthy controls (Fig. 6C).
Moreover, in contrast to their LSP1 levels, RA T cells exhibited
higher migration in transwell chambers with 10% FBS or SDF1
than T cells of healthy controls (Fig. 6D), which is consistent with
previous studies showing that RA peripheral T cells have a
greater migratory capacity toward inflamed joints containing a
variety of chemokines, including SDF1 (30). In support of this
notion, LSP1+ cells were frequently noted in the CD3+ T-cell
zone of RA synovial tissues (Fig. 6E). Double immunofluores-
cence staining of RA synovium revealed that LSP1-expressing
cells were also positive for CD3 (Fig. 6F), indicating that CD3+
T cells express LSP1 in RA synovia.
Discussion
Changes in DNA copy number, whether confined to specific
genes or affecting whole chromosomes, can have an impact on
biological homeostasis and influence interindividual differences
in the susceptibility to human disorders, especially to autoimmune
diseases (12–14). Even though a number of risk loci have been
identified as genetic factors of RA through GWASs (11, 35), it is
still unclear how CNV is related to the immune dysfunction, in-
creasing the susceptibility of autoimmune diseases. Presently, we
explored the RA-associated CNVs by a GWAS approach using
SNP array analysis and identified a significant association of LSP1
deletion variants with RA. Consistent with earlier studies of other
genes (36, 37), LSP1 protein expression levels in the present study
correlated positively with the copy number status of the LSP1
gene. Importantly, LSP1 is critically involved in chronic T-cell–
dependent inflammatory arthritis, functioning as a negative reg-
ulator of T-cell migration in mice and humans. To our knowledge,
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Fig. 4. Enhanced inflammation and T-cell migration in Lsp1-deficient mice
with DTH. (A) Increased foot thickness in Lsp1-deficient mice. Lsp1-deficient
(n = 15) and WT mice (n = 15) were sensitized s.c. with mBSA (200 μg) plus
complete Freund’s adjuvant (CFA). One week after sensitization, mBSA
(100 μg) was injected again into the footpads of each mouse. Footpad
thickness was measured 24 h after the second challenge (***P < 0.005 vs. WT
mice). (B and C) Histology of footpads of mice with DTH reaction. Sections of
footpads challenged with solvent only (Left) or mBSA (Middle and Right)
were stained with H&E (Upper) or anti-CD3 Ab (Lower). (B) Representative
with significantly increased T-cell infiltration in the epidermis and dermis
identified in Lsp1-deficient mice (C). (Scale bar: 100 μm.) Simultaneously,
mBSA-specific IgG levels in the sera were determined by ELISA (Bottom). (D)
Increase in the number of CD4+ T cells in lymph nodes of Lsp1-deficient mice.
The proportion of CD4+ cells in the spleen and lymph node was determined by
flow cytometry 7 d after the second antigen challenge. Representative dot
plots are shown (Bottom). (E and F) Migration of antigen-activated CD4+ T
cells (5 × 105 cells), which were obtained from the spleen and lymph node of
Lsp1-deficient and WT mice with DTH. The number of migrated cells was
counted manually. Data are the mean ± SEM of three independent experi-
ments (*P < 0.05 and **P < 0.01 vs. WT mice).
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Fig. 5. Aggravation of AIA in Lsp1-deficient mice. (A) Increase in ankle
swelling in Lsp1-deficient mice. AIA was induced in Lsp1-deficient (n = 10)
and WT mice (n = 10), which had been already sensitized twice with mBSA
plus CFA, by injection of mBSA into the ankle joints. Footpad and ankle
diameters were measured by using microcalipers at days 1 and 3 after the
intraarticular injection. (B) Levels of serum anti-mBSA Ab (IgG) determined
by ELISA 7 d after AIA induction. Data are expressed in OD units. (C and D)
Increase in T-cell infiltration in Lsp1-deficient mice. Seven days after AIA
induction, ankle joints were removed and stained with H&E (Left) and anti-
CD3 Ab (Right). Lsp1-deficient mice showed increased infiltration of mono-
nuclear leukocytes, including T cells, in the synovial membrane and joint
space, compared with WT mice. Data are the mean ± SEM of three in-
dependent experiments (*P < 0.05, **P < 0.01, and ***P < 0.005 vs. WT
mice). (Scale bar: 100 μm.)
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our work is the first to demonstrate how CNV contributes to
immune dysfunction and a disease susceptibility phenotype.
The copy-loss CNV encompassing the LSP1 gene was reported
in a previous CNV GWAS of hepatocellular carcinoma (38). The
same group has demonstrated that LSP1 plays as a negative
regulator of proliferation and migration of hepatoma cells (39),
which supports our findings. The existence of the CNV encom-
passing the LSP1 gene was also identified in a study by The
Wellcome Trust Case Control Consortium; however, it was not
associated with RA (40). In that study, all LSP1 CNVs were gain
variants, whereas we detected gain and deletion variants, and
only the deletion variants showed significant association with
RA. CNV calling can be dependent on the types of array plat-
forms and analytic tools (41). Indeed, a study has reported that
different analytic tools applied to the same raw data yield CNV
calls with <50% concordance (41), which indicates the impor-
tance of proper candidate CNV validation.
With this in mind, we performed a strict qPCR validation with a
larger cohort (764 patients with RA and 1,224 control subjects) to
compensate for the potential limitation of the size of the discovery
set. Additionally, to exclude the possibility that an LSP1 deletion
variant might be the case for only Korean patients with RA, we
also studied a cohort of white patients. As a result, a significant
association of LSP1 CNV with RA susceptibility was replicated in
both cohorts, which supports the reliability of our data and sug-
gests that such association is not specific to Asian populations.
Interestingly, in a subgroup analysis performed in 427 Korean
patients with RA whose serum rheumatoid factor (RF) titers were
available, we found that RF(−) patients (n = 139) had a greater
frequency of LSP1 deletion variants than RF(+) patients (n = 288;
18.7% vs. 6.9%, respectively; P < 0.001). A similar result was
observed among patients without anti-cyclic citrullinated peptide
autoantibody (16.5% vs. 5.8%, P = 0.002, n = 373). These data
suggest that LSP1 insufficiency may contribute more significantly to
the pathogenesis of seronegative RA, and warrant further in-
vestigation to determine if LSP1 low copy reflects certain pheno-
types of patients with RA, such as early onset, rapidly progressive,
and HLA-susceptible allele [i.e., (+)] subgroups.
It has been reported that LSP1 is a Ca2+-activated, intracel-
lular filamentous actin-binding protein that interacts with the
cytoskeleton (21). As Ca2+ is one of the key signals for T-cell
activation and the infiltration of Ca2+-activated T cells into joint
tissue is an essential component of the pathogenesis of RA (3, 4,
30), we set out to elucidate the pathological role and clinical
relevance of altered LSP1 expression in RA in terms of T-cell
biology. We confirmed the intracellular expression of LSP1 in
normal CD4+ and CD8+ T cells and Jurkat T cells (18). LSP1
expression was up-regulated upon TCR ligation as well as mito-
genic stimulation promoting Ca2+ flux, such as PMA plus ion-
omycin or PHA, which is in line with a previous report that Ca2+
signaling is required for LSP1 up-regulation (24). Notably, the
proinflammatory cytokine TNF-α also increased LSP1 expression.
Given the lower LSP1 expression in patients with RA despite the
higher levels of proinflammatory cytokines than in healthy subjects
(Fig. 6 A and B), these results suggest that a genetic component of
CNV, rather than proinflammatory cytokines, dominantly affects
LSP1 expression at least in peripheral RA T cells.
Previous studies have suggested the negative regulatory effects
of LSP1 on neutrophil adhesion, polarization, and migration (19,
20), but the role of LSP1 on T-cell biology remains unclear. To
address this issue, we performed gene expression profiling of Lsp1-
sufficient and deficient T cells, conditioned with TCR stimulation.
A comparative analysis of gene expression profiles revealed that
migration-related cellular processes were predominantly enriched
by the DEGs in Lsp1-deficient T cells, which was subsequently
confirmed by qPCR for the selected target genes. Moreover, we
first found that cytokine–cytokine receptor interaction, response to
wounds, innate immune response, and Ca2+ ion homeostasis also
were governed by the LSP1 gene.
The mechanistic basis of regulated T-cell migration involves a
chemokine gradient and the differential expression of chemokine
receptors on naive and activated T cells (42). SDF1, MCP-1, and
IL-6 are the main chemokines responsible for T-cell migration
and are present at high levels in the synovial tissue or fluid of
patients with RA (43–47). We found that LSP1-overexpressing
Jurkat T cells exhibited a reduced chemotactic response
to SDF1. Conversely, Lsp1-deficient primary T cells showed an
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Fig. 6. Decreased LSP1 expression in RA T cells. (A) Representative dot plots
show LSP1 expression in the CD4+ and CD8+ T cells of healthy controls and
patients with RA. PBMCs were stained with PE-labeled anti-CD4 Ab or APC-
labeled anti-CD8 Ab, and then stained again with FITC-conjugated anti-LSP1
Ab. (B) LSP1 expression in T cells of patients with RA and healthy controls as
determined by flow cytometry. (Left) Comparison of LSP1 expression in pe-
ripheral T cells between healthy controls (n = 12) and patients with RA (n =
12). (Right) Comparison of frequency of LSP1-expressing T cells between
synovial fluid mononuclear cells (SFMCs; n = 7) and PBMCs (n = 7), which
were obtained simultaneously from each patient with RA (*P < 0.05, **P <
0.01, and ***P < 0.001). (C) LSP1 induction in T cells of patients with RA (n =
4) vs. healthy controls (HC; n = 4) when stimulated with PHA (5 μg/mL) for
12 h or stimulated with anti-CD3 Ab plus anti-CD28 Ab for 48 h. Gray-colored
histogram indicates isotype control (*P < 0.05 and **P < 0.01). (D) Increased
T-cell migration in patients with RA. T cells were isolated from PBMCs of
patients with RA (n = 6) and healthy controls (n = 6) by using anti-CD3
magnetic beads and incubated in transwell chambers in the presence or
absence of 10% FBS or SDF1 (100 ng/mL). The number of migrated cells was
counted manually. Data are the mean ± SEM (*P < 0.05 and **P < 0.01).
(E) Immunohistochemical staining of RA synovia (RA-1 and RA-2) using anti-
LSP1 Ab or anti-CD3 Ab. (Scale bar: 100 μm.) (F) Double immunofluorescence
staining of RA synovia (RA-1 and RA-2) was performed by using Abs against
LSP1 or CD3. Sections were stained subsequently with Cy3-conjugated anti-
IgG (red) for anti-CD3 Ab and Alexa 488-conjugated anti-IgG (green) for
anti-LSP1 Ab, respectively. In merged images, LSP1+ cells were costained
with anti-CD3 Ab in yellow. In the same images, the nucleus was stained with
DAPI in blue. (Scale bars: 20 μm.)
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enhanced migratory capacity upon SDF1 stimulation, which was
not caused by differential levels of expression of CXCR4, a
specific SDF1 receptor. These observations are in accordance
with our results regarding gene expression profiling of Lsp1-
deficient T cells. Thus, we concluded that LSP1 is a negative
regulator of T-cell migration.
What is the downstream target of LSP1 responsible for T-cell
migration? Evidence is emerging that, unlike MCP-1 and IL-6,
SDF1-induced T-cell migration is mediated by ERK activation
(43–45). In fact, the ERK pathway has been implicated in the
migration of numerous cell types (48). The ERK pathway in-
hibitors PD98059 and U0126 inhibit cell migration in response to
cell matrix proteins (e.g., fibronectin, vitronectin), growth factors
(e.g., VEGF, EGF), and other stimuli, such as FCS (48). In the
present study, ERK phosphorylation was blocked in LSP1-
overexpressing T cells. Additionally, the enhanced migratory
propensity of Lsp1-deficient T cells was almost completely ab-
rogated by treatment with an ERK inhibitor. Moreover, as
shown in Fig. 3D, LSP1 directly bound to pERK. Collectively,
these results, together with previous reports (29, 45, 49), suggest
that LSP1 regulation of T-cell migration is attributable to de-
activation of pERK through a direct molecular contact. The
central role of ERK activation in LSP1-mediated T-cell migration
was corroborated by our data demonstrating nine ERK-dependent
target genes and nine ERK-related TFs by comparative analysis
of gene profiles.
To investigate the regulatory role of LSP1 in vivo, we used two
disease models of DTH and AIA that are mediated primarily by
activated T cells (33, 34). Lsp1-deficient mice exhibited marked
T-cell infiltration into the inflamed tissue compared with WT
mice, which correlated well with clinical severity and the levels of
antigen-specific Ab response. This is in accordance with previous
studies demonstrating increased neutrophil migration in a mouse
model of zymosan-induced arthritis and wound healing (19, 20).
It is well established that, after antigen stimulation, CD4+ T cells
enter the draining lymph nodes and participate in the primary
response, becoming central memory T cells (50). Given that
more CD4+ T cells settled in the draining lymph node of Lsp1-
deficient mice in comparison with WT mice but the overall fre-
quency of memory or naive T-cell subsets did not differ, it is
likely that a loss of Lsp1 has an intrinsic effect on CD4+ T-cell
migration with no impact on expansion and differentiation.
Of note, T cells from peripheral blood of patients with RA
expressed less LSP1 protein than those from healthy individuals.
Considering that LSP1 negatively regulates T-cell migration, this
result offers an intriguing explanation of how RA T cells accu-
mulate into inflamed joints. RA T cells with defective LSP1 ex-
pression have a strong migratory propensity and can readily move
along the SDF1 gradient into the affected joints. However, when
T cells have entered the inflamed joints, they may acquire in-
creased LSP1 expression following antigenic stimulation and the
presence of proinflammatory cytokines, such as TNF-α, and then
settle in the inflamed synovium. This notion is supported by our
findings of higher LSP1 expression in paired synovial T cells than
in peripheral T cells of patients with RA (Fig. 6B). If this is the
case, the intrinsic tropism of RA T cells to the inflamed synovium,
which could be predetermined genetically by CNV, may favor the
stable interaction of T cells with other immune cells, including
B cells to produce antigen-specific Ab, macrophages, and syno-
viocytes, to drive the self-perpetuation of chronic inflammation.
To our knowledge, our work is the first to demonstrate how
CNV results in immune dysfunction and a disease phenotype,
highlighting the importance of such genetic variants in the
pathogenesis of autoimmune diseases. However, this study has
some limitations. First, the LSP1 copy number loss was found in
only 10.1% of RA cases, which indicates that the majority of
patients with RA do not have an LSP1 low copy and that other
genes or mechanisms may be involved in the increased T-cell
migration in RA. Moreover, epigenetic dysregulation of LSP1
gene, which was not assessed in this study, may contribute to RA
susceptibility together with LSP1 CNV to promote T-cell migra-
tion into the joints. Second, the animal models used in this study
are for transient and eventually self-limiting inflammatory arthri-
tis, and thus may not be accurate for chronic persistent arthritis
like RA. Furthermore, the major cellular infiltrate in RA synovia
are cells of the monocytic/macrophage lineage with appreciable
numbers of neutrophils (3). As LSP1 also has been reported to
have a role in neutrophil migration (19, 20), the immunopathology
of RA may originate from the promigratory effects of LSP1 in-
sufficiency on additional cell types besides T cells.
In summary, we identified a novel LSP1 deletion variant for
RA susceptibility through a CNV GWAS. The copy number of
LSP1 is significantly lower in patients with RA, which correlates
positively with LSP1 protein expression levels. We also showed
that LSP1 negatively regulates SDF1-induced T-cell migration by
reducing ERK activation. Loss of Lsp1 promotes T-cell migra-
tion into antigen-instilled tissues and draining lymph nodes in
mice with T-cell–dependent chronic inflammation. Moreover,
patients with RA showed diminished expression of LSP1 in pe-
ripheral T cells with increased migratory capacity, suggesting that
the defect in LSP1 signaling lowers the threshold for T-cell acti-
vation (e.g., cell migration) in patients with RA. Our data provide
previously unidentified insight into the mechanisms of increased
T-cell migration toward the inflamed synovium in RA and may
open an opportunity for the development of new drugs targeting
LSP1 in chronic inflammatory diseases. Additionally, the concept
of an association between increased T-cell migration with LSP1
CNVs and LSP1 insufficiency might extend to the pathogenesis of
other T-cell–dependent autoimmune diseases, including autoim-
mune thyroiditis, multiple sclerosis, autoimmune diabetes, and
lupus nephritis, in which abnormal lymphocyte migration is im-
portant for infiltration and retention of T cells within pathologic
sites (51).
Materials and Methods
Study Design. For the CNV GWAS analysis, 100 Korean patients with RA and 400
healthy individuals were recruited. For the independent replication of the can-
didate RA-associated CNV, 764 patients with RA (599 Korean and 165 white) and
1,224 healthy individuals (966Korean and 258white)were recruited (SI Appendix,
Table S1). LSP1 expression was confirmed from PBMCs, including T-cell subsets,
by flow cytometry and real-time qPCR. Biological processes and associated
molecules governed by LSP1 were explored through global transcriptome pro-
filing and systematic analysis comparing DEGs between LSP1-deficient T cells and
WT. Functional activity of LSP1 regulating T-cell migration was investigated by
transwell migration assay using LSP1-deficient or -overexpressing T cells. The in
vivo effect of LSP1 regulating T-cell migration on chronic inflammation was
verified in two T-cell–dependent chronic inflammation models, DTH and AIA,
using Lsp1-deficient mice. This study was performed with the approval of the
Catholic Medical Center Office of Human Research Protection Program in-
stitutional review board (no. CUMC09U034). All patients gave written informed
consent to the study protocol. The experimental procedures were approved by
the Institutional Animal Care and Use Committee of the Catholic University of
Korea.
CNV Discovery. To define CNVs, we used SNP genotyping data from the 500
discovery set. In brief, 500 ng of genomic DNA was extracted from peripheral
blood leukocytes and assayed on the Affymetrix Genome-Wide Human SNP array
5.0 (Affymetrix). Identification of CNVs was performed as described elsewhere
(52). We designated each CNV based on its copy number status as diploid, loss, or
gain. Boundaries of each CNV were determined as the distance from the linear
location of the first SNP probe to that of the last probe (NCBI36/hg18; genome.
ucsc.edu/index.html). Genomic qPCR for replication was performed as described
elsewhere (53). Details of the study subjects, definition of CNVRs, and qPCR for
genomic DNA are available in SI Appendix, Materials and Methods.
Detailedmaterials andmethods, includingmicroarray experiments, cell culture,
cloning of overexpression of LSP1 gene, induction of DTH reaction, induction of
AIA, T-cell migration assay, flow cytometry analysis of LSP1,Western blot analysis,
immunoprecipitation, immunohistochemistry, and immunofluorescence staining
are described in SI Appendix, Materials and Methods.
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